Vaxelis
Drug timelines are a Plus or Pro feature.
4 regulatory and trial events tracked for Vaxelis, covering 2021-09-05 to 2026-03-31. Get the full timeline:
Most recent: EMA Authorised: Vaxelis (Diphtheria toxoid;tetanus toxoid;Bordetella pertussis antigens: pertussis toxoid, filamentous haemagglutinin, pertactin, fimbriae Types 2 and 3;hepatitis B surface antigen produced in yeast cells;poliovirus (inactivated): type 1 (Mahoney), type 2 (MEF-1), type 3 (Saukett) produced in Vero cells/ Haemophilus influenzae type b polysaccharide (polyribosylribitol phosphate) conjugated to meningococcal protein.) — MCM Vaccine B.V.